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Abstract: Newly recognized hyperglycemia frequently occurs with acute medical illness, 
especially among patients with cardiovascular disease (CVD). Hyperglycemia has been linked 
to increased morbidity and mortality in critically ill patients, especially when it is newly rec-
ognized. Increased rates of reinfarction, rehospitalization, major cardiovascular events, and 
death in CVD patients have also been found. An expanding body of literature describes the 
benefits of normalizing hyperglycemia with insulin therapy in hospitalized patients. This article 
reviews several underlying mechanisms thought to be responsible for the association between 
hyperglycemia and poor outcomes in critically ill patients and those with cardiovascular events, 
as well as the biologic rationale for the benefits of insulin therapy in these patients.
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Introduction
Estimates from 2007 indicate that 23.6 million people in the United States (7.8%) 
have diabetes, among whom 5.7 million are undiagnosed.1 An additional 57 million 
American adults may have prediabetes (based on the prevalence of impaired fasting 
glucose).1 Hyperglycemia also frequently occurs as a result of medical illness, even 
without previously recognized diabetes – especially among critically ill patients with 
cardiovascular disease (CVD).2,3 For example, the Euro Heart Survey found that 36% 
of patients without a history of diabetes who presented with acute manifestations 
of coronary artery disease had impaired glucose tolerance; another 22% had newly 
diagnosed diabetes.3 Likewise, in a prospective analysis of patients presenting with 
acute myocardial infarction (MI) and no history of diabetes, 35% had impaired glucose 
tolerance and 31% had unrecognized diabetes.2
Even normoglycemic patients or those with well-controlled diabetes before illness 
onset may develop hyperglycemia in response to acute metabolic stress, suggesting 
an irregularity in homeostatic regulation mechanisms that worsens with severity of 
illness.4 In a prospective cohort study of 100 patients admitted to a medical intensive 
care unit (ICU), including 51 patients with normal glucose levels at baseline, nearly 
all experienced some degree of hyperglycemia.4 The substantial influence of even 
small increases in glucose levels was evident in that patients with glucose levels in 
the higher ranges of normoglycemia before admission had more frequent and more 
severe hyperglycemia in the ICU than did those with glucose levels within the lower 
range of normoglycemia (Figure 1).4Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Figure 1 Percentage of time (median and quartile bounds) over glucose thresholds varied in patients admitted to the medical intensive care unit according to low-normal 
(HbA1C , 5.5%), high-normal (5.5% # HbA1C , 6.5%), and abnormal baseline glucose levels. Glucose threshold values can be converted to conventional units (mg/dL) by 
multiplying by the conversion factor 0.0555.
Copyright © 2004. Adapted with permission from AM College of Chest Medicine. Cely CM, Arora P, Quartin AA, Kett DH, Schein RM. Relationship of baseline glucose 
homeostasis to hyperglycemia during medical critical illness. Chest. 2004;126(3):879–887.4
Abbreviation: HbA1C, glycated hemoglobin. 
It is now recognized that uncontrolled hyperglycemia has 
a negative effect on clinical outcomes in hospitalized patients. 
Many studies over the past 2 decades have demonstrated 
that short- and long-term mortality rates following acute 
MI are significantly higher when hyperglycemia is pres-
ent, with or without established diabetes.5–11 This suggests 
that hyperglycemia, rather than diabetes status, influences 
morbidity and mortality risk. In fact, a study by Umpierrez 
and colleagues observed that hospitalized patients (admitted 
to general wards) with newly discovered hyperglycemia had 
significantly higher in-hospital mortality than those with nor-
moglycemia or previously diagnosed diabetes (16% versus 
1.7% and 3%, respectively, P , 0.01). Newly recognized 
hyperglycemia was also associated with worse functional 
outcomes.12 Patients exhibiting stress hyperglycemia upon 
admission with acute MI have been shown to have a height-
ened risk of congestive heart failure (CHF) or cardiogenic 
shock compared with patients without hyperglycemia.11 This 
association between stress hyperglycemia and risk of CHF 
or shock has been observed in patients without diabetes 
and not present in patients with diabetes.11 In a retrospec-
tive study of 197 patients with acute MI without diabetes, 
admission plasma glucose level was an independent predictor 
of hospitalization for heart failure (P = 0.0034).9 In addition, 
a recent study showed that insulin resistance is an indepen-
dent predictor of left ventricular diastolic disorder (LVDD) 
prevalence and severity in patients without diabetes. Insulin 
resistance was associated with: metabolic syndrome, LVDD, 
and obesity. The authors indicated that in patients with insulin 
resistance, the risk for LVDD is already elevated, even before 
the development of diabetes, therefore, these patients may 
be a target group for heart failure prevention.13
Several landmark studies have demonstrated that aggres-
sive treatment of hyperglycemia with insulin therapy can 
reduce morbidity and mortality in critically ill patients,14,15 
patients undergoing coronary artery bypass graft (CABG),10 
and post-MI patients with diabetes.16 These data have 
increased emphasis on managing hyperglycemia in hospi-
talized patients – especially the critically ill and those with 
CVD – and have led the American Diabetes Association 
(ADA) to update its guidelines for managing in-hospital 
hyperglycemia. The ADA 2010 Standards of Medical Care 
in Diabetes now recommend that insulin therapy be initi-
ated for persistent hyperglycemia starting at #10.0 mmol/L 
(#180 mg/dL).17 Blood glucose levels should be maintained 
at 7.8 to 10.0 mmol/L (140 to 180 mg/dL) for most critically Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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ill patients and are most effectively achieved via intravenous 
insulin protocols.17 The 2009 American Association of 
Clinical Endocrinologists/ADA Consensus Statement on 
Inpatient Glycemic Control recommends a starting threshold 
no higher than 10.0 mmol/L (180 mg/dL). Once IV insulin 
therapy has begun, blood glucose should be maintained 
between 7.8 and 10.0 mmol/L (140 and 180 mg/dL), with 
targets ,6.1 mmol/L (,110 mg/dL) not recommended.18
It should be noted that insulin therapy is not without poten-
tial harm. One meta-analysis found that tight glucose control 
in critically ill patients resulted in an increased risk of hypo-
glycemia.19 A small (N = 13) study of healthy males designed 
to determine the body’s response to the stress of hypoglycemia 
found an increase in proinflammatory cytokines, markers for 
lipid peroxidation, reactive oxygen species, and leukocytosis. 
Further examination is necessary to determine whether this is 
an adaptive response to the body’s efforts to maintain glucose 
homeostasis under such stress.20
This paper reviews the underlying mechanisms believed 
to be responsible for the association between hyperglycemia 
and poor outcomes in critically ill patients and patients with 
cardiovascular events, as well as the biologic rationale for 
the benefits of insulin therapy in these patients.
Hyperglycemia, inflammation,  
and atherogenesis
Many data from in vitro and epidemiologic studies have sug-
gested that insulin is potentially atherogenic.21–23 This arose 
from the finding that most patients with diabetes and at risk 
for vascular complications exhibit hyperinsulinemia due 
to compensation for insulin resistance, which is associated 
with atherogenic risk (eg, dyslipidemia, hypertension, pro-
coagulant state). The notion that insulin itself is cardiotoxic 
or vasculotoxic, however, is inconsistent with more recent 
clinical outcomes, especially those observed in long-term 
follow-up of studies such as the United Kingdom Prospective 
Diabetes Study (UKPDS).24 Researchers now believe that 
hyperglycemia rather than the hyperinsulinemia of diabetes 
actually induces inflammatory changes and oxidative stress, 
which harm cardiovascular and endothelial function.25–29 
Shown in Table 1 are the deleterious effects of hyperglycemia 
on endothelial and vascular function in patients with type 
1 and type 2 diabetes with associated hyperlipidemia and 
insulin resistance.30
Insulin resistance, one of the 2 major contributors to 
type 2 diabetes, appears to play an important role in chronic 
cardiovascular risk. Its exact influence in atherogenesis is 
poorly understood, but several relationships appear to be 
Table  1  Deleterious  effects  of  hyperglycemia  on  endothelial 
and vascular function (as seen in patients with type 2 diabetes in 
association with dyslipidemia and insulin resistance)61
↑ AGEs activation ↑ vascular permeability
↑ Inflammatory cytokines
↑ Tissue factor
↑ Thrombomodulin
↓ Nitric oxide ↑ vasoconstriction
↑ Platelet adhesion
↑ Leukocyte adhesion
↑ vascular smooth muscle cell growth
↑ PKC activation ↑ Endothelin-1
↑ Renin-angiotensin system
↑ vascular permeability
↑ Platelet and coagulation system 
activation
↑ iiB/iiia receptors
↑ Clotting factors
↑ PAi-1
↓ Antithrombin iii
↓ PPAR activation ↑ NFkB
↑ ROS
↑ Inflammatory cytokines
Abbreviations: AGEs, advanced glycation end products; PKC, protein kinase C; 
PPAR,  peroxisome  proliferator-activated  receptor;  iiB/iiia,  glycoproteins  iiB/iiia; 
PAi-1, plasminogen activator inhibitor-1; NFkB, nuclear factor kB; ROS, reactive 
oxygen species.
involved. Insulin resistance, inflammation, and atherogenesis 
are linked by a common series of metabolic defects, includ-
ing dyslipidemia and hypercoagulability.31 With insulin 
resistance, especially in patients with 4 or 5 aspects of the 
metabolic syndrome, deregulation of proinflammatory and 
anti-inflammatory cytokine production (eg, increased levels 
and activity of interleukin-6 and tumor necrosis factor-α) 
contributes to oxidative stress. The resultant generation 
of reactive oxygen species, combined with hypercholes-
terolemia and insulin resistance, apparently contributes to 
endothelial dysfunction.
Mechanisms involved in endothelial dysfunction in 
patients with diabetes, its impact on vascular complications, 
and potential targets of therapeutic intervention have been 
reviewed elsewhere.28,29 Relatively acute endothelial dysfunc-
tion and longer-term endothelial damage result from oxidative 
stress. Insulin therapy may reverse short-term endothelial 
dysfunction.32 Figure 2 shows a schematic of how insulin 
infusion therapy to treat hyperglycemia during critical illness 
may protect the endothelium by downregulation of inducible 
nitric oxide synthase.32 Subanalysis of a large, randomized 
controlled study of intensive insulin therapy in critically ill 
patients demonstrated how intensive insulin therapy   suppressed 
inducible nitric oxide synthase gene expression in postmor-
tem liver and skeletal muscle (via reduced nuclear factor kB 
[NF-kB] activation), and reduced circulating nitric oxide levels 
in survivors and nonsurvivors. Biochemical changes reflected Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Figure 2 Model for effects of intensive insulin therapy on endothelial function in critically ill patients. Low concentrations of nitric oxide (NO), normally generated by 
endothelial nitric oxide synthase (eNOS), are likely to be beneficial for the endothelium and organ function. However, high concentrations of NO produced by upregulation 
of inducible nitric oxide synthase (iNOS) may contribute to excessive vasodilation, endothelium dysfunction, and tissue injury. Prevention of hyperglycemia during critical 
illness via insulin infusion may protect the endothelium by modifying eNOS and/or iNOS expression and activity.
Copyright © 2005. Reprinted with permission from American Society for Chemical investigation. Langouche L, vanhorebeek i, vlasselaers D, et al. intensive insulin therapy 
protects the endothelium of critically ill patients. J Clin Invest. 2005;115(8):2277–2286.32
Abbreviations: EC, endothelial cell; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; NFkB, nuclear factor kB; ROS, reactive oxygen species; vEGF, 
vascular endothelial growth factor.
reduced endothelial activation, which contributes to the risk of 
organ failure and death in critically ill patients. The endothelial 
effects in this subanalysis explained a statistically significant 
portion of improved patient outcomes clinically associated 
with intensive insulin therapy.32,33
Using a model of critical illness, Ellger et al suggested that 
glycemic control helps maintain proper endothelial vasodilatory 
function indirectly through the actions of arginine and asym-
metrical-dimethylarginine.34 Asymmetrical-  dimethylarginine 
primarily cleared by dimethylarginine-dimethylaminohydro-
lase is an endogenous inhibitor of nitric oxide synthetase that 
increases during critical illness and predicts mortality and 
morbidity. Although insulin does not directly affect   dimethy
larginine-dimethylaminohydrolase, glucose control restores 
its activity, whereas uncontrolled hyperglycemia reduces it. 
Additionally, inhibition by insulin of plasminogen activator 
protein-1, an inhibitor of fibrinolysis, may help dissolve clots 
that form in acute MI.35
Longer-term biochemical or structural endothelial damage 
(see revised classic model of atherosclerosis in Ross36) can 
initiate a cascade of atherogenic activity in the vascular wall, 
including entrapment of atherogenic molecules, triggering of 
immunologic activity, promotion of adhesion molecules, and 
development of lipid-laden foam cells that form the basis for 
plaque production.31 Thus insulin resistance initiated by poor 
control of glycemic levels, rather than by insulin itself, may 
stimulate atherosclerosis. In the UKPDS intensive-treatment 
arm neither insulin nor insulin secretagogues were associated 
with increased vascular events, MI, or death.37 Interestingly, 
the long-term outcome of the UKPDS intensive glucose policy 
for sulfonylureas and insulin has recently been reported to 
show improvement in all-cause mortality, diabetes-related 
death, and significant reduction in MI. The reduction occurred 
despite the intensive policy group having had similar glycemic 
control over the past 10 years; it may represent a “legacy 
effect” of earlier glycemic control.24,38
Clinical studies have shown that patients with chroni-
cally elevated insulin levels due to insulin therapy have 
reduced insulin resistance but no increased risk of athero-
sclerosis or CVD. In some cases, individuals benefit from Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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insulin exposure, experiencing reduced oxidative stress 
and improved endothelial function (ie, anti-inflammatory 
benefit).37,39 de Jager and colleagues linked the develop-
ment of type 2 diabetes to the combination of endothe-
lial dysfunction and low-grade inflammation, reporting 
a .40% increased risk of cardiovascular mortality with 
this combination.40
Furthermore, elevated glucose levels have been shown to 
promote the production of reactive oxygen species, significantly 
increasing its generation by both mononuclear and polymor-
phonuclear cells within 3 hours after glucose challenge.41,42 
Oral glucose intake (glucose tolerance test) also significantly 
increased binding of the transcription factor NF-kB in mono-
nuclear cell nuclear extracts, indicating that pro-oxidant and 
proinflammatory activity follows the intake of excessive macro-
nutrients.42 In another study, oxidative stress, as estimated from 
urinary excretion of free 8-iso prostaglandin F2α, was higher 
in patients with hyperglycemia resultant from type 2 diabetes 
than in nondiabetic controls matched for age and sex.43 These 
pathophysiologic findings confirm a relationship between 
variations in glucose exposure, endothelial dysfunction, and 
atherogenesis independent of insulin levels. When 1548 patients 
admitted to a surgical ICU received insulin infusion or con-
ventional therapy to achieve blood glucose levels of 4.4 to 
5.6 mmol/L (80 to 100 mg/dL), lowering blood glucose rather 
than insulin dose reduced mortality (P , 0.0001).44
The role of insulin infusion versus glucose-insulin-
  potassium (GIK) therapy to achieve glycemic control and 
improve outcomes in critically ill patients has been inves-
tigated and debated.27,45 In general, GIK infusions may 
induce hyperglycemia, offset insulin’s beneficial effects, 
and fail to control glucose levels. Insulin infusions may 
lower the proinflammatory effects of glucose and induce the 
  anti-inflammatory effects of insulin.27,45
Recent studies in patients with type 2 diabetes have exam-
ined the hypothesis that insulin infusions may affect toll-like 
receptors (TLRs), major determinants of inflammatory response 
to viral, fungal, and bacterial pathogens.27 Insulin infusions 
significantly suppressed messenger RNA levels by .25% for 
several of these receptors, including TLR-1, -2, -4, -7, and -9, 
within 2 hours (P , 0.05 for all). DNA binding of PU.1, a 
major transcription factor regulating many TLR genes, was 
also suppressed (24% ± 10%, P , 0.05).46
Role of insulin in cardiovascular 
disease
Several investigators have studied the impact of insulin on 
markers of atherosclerosis, indicating a compelling benefit. 
A number of studies have shown a significant reduction 
in C-reactive protein increase in patients with CVD who 
were treated with insulin, during ST-segment elevation 
MI (P , 0.05) and CABG surgery (P , 0.05).47,48 These 
results indicate that insulin is associated with a decrease 
in the systemic inflammatory response. In a recent study 
involving 88 patients with a first MI who were scheduled to 
undergo CABG surgery (50 hyperglycemic patients and 38 
normoglycemic [control] patients),33 hyperglycemic patients 
were randomized to intensive glycemic control (IGC; n = 25; 
glucose 4.4 to 7.8 mmol/L [80 to 140 mg/dL]) or conventional 
glycemic control (CGC; n = 25; glucose: 10.0 to 11.1 mmol/L 
[180 to 200 mg/dL]) for 3 days before surgery. Results 
showed that, compared with IGC patients, CGC patients 
had significantly higher infarct segment length (P , 0.05), 
myocardial performance index (P , 0.02), and wall motion 
scores (P , 0.01) but lower ejection fraction (P , 0.05). In 
the immediate postinfarct period, IGC was associated with a 
significant reduction of inflammatory cytokines, NF-kB acti-
vation, oxidative stress, and apoptotic cell death compared 
with CGC33. It is likely that treatment of hyperglycemia with 
insulin acts to counteract inflammatory response and poorer 
outcomes in critically ill patients by a dual mechanism of a 
direct anti-inflammatory effect of insulin as well as lowering 
the proinflammatory effects of glucose.27
Patients with type 2 diabetes randomized to placebo 
metformin, placebo metformin and insulin glargine, met-
formin only, or metformin and insulin glargine achieved 
significant reductions in blood glucose and glycated hemo-
globin (HbA1C) levels and C-reactive protein in all treatment 
groups. However, reductions in C-reactive protein were 
not significantly different among patients using insulin 
(change from baseline: −11.8%; 95% confidence interval 
[CI]: −18.7% to −4.4%) compared with no insulin (−17.5%; 
95% CI: −23.9% to −10.5%) (for difference, P = 0.25), or 
among patients using metformin (−18.1%; 95% CI: −24.4% 
to −11.1%) compared with placebo (−11.2%; 95% CI: −18.1% 
to −3.7%) (for difference, P = 0.17). The authors note this 
study was limited to outpatients with stable type 2 diabetes 
and results may not pertain to the potential anti-inflammatory 
effects of insulin in critically ill patients.49
Thus far, no clinical studies examining the effects of 
insulin detemir on cardiovascular variables including lipid 
parameters or changes in carotid intima-media thickness 
have been published. However, the Copenhagen Insulin and 
Metformin Therapy (CIMT) trial will measure the change 
in carotid intima-media thickness, and other cardiovascular 
variables, following 18 months of treatment with insulins Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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detemir and aspart.50 Carotid intima-media thickness often 
serves as a proxy for progression of macrovascular disease. 
The technique involves imaging an arterial wall segment of 
the common carotid arteries.50 Vehkavaara and Yki-Jarvinen 
studied the vascular effects of insulin glargine added to 
metformin in 11 patients whose type 2 diabetes was poorly 
controlled by metformin monotherapy.51 The patients receiv-
ing glargine experienced improvement in both endothelial-
dependent and endothelial-independent vasodilation at   
3.5 years compared with noninsulin-treated control patients 
with diabetes (P , 0.02 for both treatment comparisons).51 
In another study, insulin aspart improved endothelial function 
in patients with type 2 diabetes by preserving flow-mediated 
vasodilation after a standard test meal (P , 0.01).52 Lautamaki 
and coworkers studied the effects of insulin infusion on 
endothelial activity in 43 patients with type 2 diabetes and 
a history of angina.53 Using traditional and nuclear imaging 
techniques, they observed increased myocardial blood flow in 
both ischemic and nonischemic regions, which helps improve 
endothelial function and preserve cardiac health.53
Finally, the Epidemiology of Diabetes Interventions and 
Complications (EDIC) study, an observational follow-up 
of the Diabetes Control and Complications Trial (DCCT), 
evaluated how aggressive insulin therapy affects cardio-
vascular architecture in patients with insulin-treated type 
1 diabetes.54 Patients randomly assigned to conventional 
diabetes therapy (611; HbA1C goal, ,9.0%) were compared 
with patients receiving aggressive treatment (618; HbA1C 
goal, ,7.2%). Aggressive insulin therapy significantly 
reduced the degree of progression of intima-media thicken-
ing in the carotid artery (0.032 versus 0.046 mm; P = 0.01) 
and in the combined common and internal carotid arteries 
(−0.115 versus 0.007 mm; P = 0.2) after 6 years, compared 
with conventional diabetes therapy.54 Although this change 
has not been linked directly to cardiovascular outcome rates, 
the findings suggest a potential CVD benefit.
The major cardiovascular event rate has also been shown 
to be reduced in long-term follow-up of the EDIC study. 
During a mean 17 years of follow-up in the DCCT, 46 CVD 
events occurred in 31 patients intensively treated with a 
mixed-intermediate or rapid-acting insulin, compared with 
98 events in 52 patients who received conventional treat-
ment. There was a 42% decrease in cardiovascular events 
and a 57% decrease in the risk of nonfatal MI, stroke, or 
death from CVD in the intensive treatment group.55 Signifi-
cant reductions in total cholesterol, low-density lipoprotein 
(LDL) cholesterol, and triglyceride levels also have been 
observed in the intensive-treatment group (P # 0.01), as 
well as a reduction in the development of LDL cholesterol 
levels .4.1 mmol/L.56
Ongoing studies, such as the ORIGIN (Outcome 
Reduction With Initial Glargine Intervention) trial will deter-
mine if maintaining normoglycemia with insulin glargine can 
reduce the risk of cardiovascular morbidity and/or mortality 
among outpatients with impaired fasting glucose, impaired 
glucose tolerance, or early type 2 diabetes who are at high risk 
for vascular disease.57 The ACCORD (The Action to Control 
Cardiovascular Risk in Diabetes)58 and ADVANCE (Action 
in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation)59 study groups have 
recently published data indicating that intensive glycemic 
control (HbA1C , 6.0% or #6.5%, respectively) in patients 
with type 2 diabetes (ACCORD; mean age, 62 years;   duration 
of diabetes, 10 years; ADVANCE; mean age, 66 years; dura-
tion of diabetes, 8 years) at high cardiovascular risk failed to 
reduce major cardiovascular events, and that it was actually 
associated with higher mortality (the ACCORD study). The 
implications of these results are not yet clear. Although 
future studies are unlikely to show improvements in CVD 
outcomes when HbA1C values are #6.5%, current evidence 
justifies maintaining HbA1C goals at ,7.0% to reduce micro-
vascular and neurologic morbidity and suggests that doing 
so may reduce CVD complications in the long term.60 It is 
important to note, however, that these studies examined 
outpatients with type 2 diabetes, as opposed to critically ill 
patients with hyperglycemia (discussed in this review) treated 
with a variety of glucose-lowering drugs, and the studies were 
therefore not specifically testing the effects of insulin therapy. 
Only 40.5% of patients in the intensive control arm of the 
ADVANCE study were prescribed insulin.59 Furthermore, 
more time may be needed for glycemic control to realize the 
reduction of MI risk. The 10-year follow-up of the UKPDS 
reported patients with type 2 diabetes who control glucose 
by intensive therapy (sulfonylurea or insulin, or metformin 
in overweight patients) had significant risk reductions for MI 
(15%, P = 0.01) and death from any cause (13%, P = 0.007) in 
the sulfonylurea-insulin group when compared with patients 
receiving conventional therapy (dietary restrictions); the 
metformin group also had significant risk reductions for MI 
(33%, P = 0.005).24
Summary
Hyperglycemia substantially increases the risk of morbidity 
and mortality among critically ill patients with CVD. Contrary 
to previous theories, the negative effect of hyperglycemia 
related to stress or uncontrolled diabetes on long-term Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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outcomes in this patient subpopulation appears to be linked 
to the proinflammatory, oxidant stress, endothelial dysfunc-
tion, and atherogenic effects of hyperglycemia rather than to 
any metabolic alteration associated with hyperinsulinemia. 
Recognition of this alternative pathophysiologic paradigm 
and improved outcomes in patients treated with insulin have 
led to widespread interest in maintaining adequate glucose 
control in critically ill patients, and intense investigation into 
the best means by which to achieve relative normoglycemia 
throughout periods of acute illness.
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